Status:

COMPLETED

Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan

Lead Sponsor:

University of Oxford

Collaborating Sponsors:

National Malaria and Leishmaniasis Control Program, Afghanistan

Mahidol University

Conditions:

Vivax Malaria

Eligibility:

All Genders

6+ years

Phase:

PHASE4

Brief Summary

This is an open label two-arm randomized prospective study of two treatments for P. vivax malaria. Patients meeting study inclusion criteria will be enrolled and allocated either chloroquine alone or ...

Detailed Description

Globally more than 100 countries are endemic of malaria and about 60% of world population are at risk of getting the infection while around 10% are harboring malaria parasite in their blood stream. Of...

Eligibility Criteria

Inclusion

  • Adults and children \>6 months
  • Negative pregnancy test in women at risk of pregnancy
  • Microscopic diagnosis of Plasmodium vivax mono-infection (\>200/µl asexual forms)
  • Axillary temperature ≥37.5°C or oral/rectal temperature ≥38°C or history of fever within the last 24 hours
  • Ability to swallow oral medication
  • Participant (or parent/guardian if \<18 years old) is willing and able to give written informed consent
  • Ability (in the investigator's opinion) and willingness of patient or parent/guardian to comply with all study requirements

Exclusion

  • Severe malaria (see WHO definition)
  • Patients with microscopic diagnosis of co-infection with Plasmodium falciparum
  • Haemoglobin concentration \<8g/dl
  • Presence of any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study e.g. other acute febrile conditions or chronic disease
  • Pregnancy or lactation
  • History or phenotypic test compatible with severe G6PD deficiency
  • History of hypersensitivity to any of the drugs being tested

Key Trial Info

Start Date :

August 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2014

Estimated Enrollment :

593 Patients enrolled

Trial Details

Trial ID

NCT01178021

Start Date

August 1 2009

End Date

February 1 2014

Last Update

January 15 2019

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Provincial Malaria Control Centers (MRC)

Maymana, Faryab Province, Afghanistan

2

Provincial Malaria Control Centers (MRC)

Jalalabad, Afghanistan

3

Provincial Malaria Control Centers (MRC)

Kunduz, Afghanistan

Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan | DecenTrialz